Provider: Thomson Reuters Stock Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Access Bio Inc Issues FY 2013 Outlook Below Analysts' Estimates
Access Bio Inc announced that it expects its fiscal year 2013 revenue and operating profit to record KRW 46.4 billion and KRW 12.1 billion, respectively. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of KRW 47.20 billion for the fiscal year 2013.
Latest Key Developments in Medical
- Share this
- Digg this